Gilead Q3 Sales Rise Driven by HIV Products, Revenue Guidance Raised
Gilead Sciences reported a 13% increase in Q3 product sales to $8.3 billion and raised full-year revenue guidance, offset by a significant decline in cash balances due to acquisitions and dividends.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed